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P  0.0001), and a significantly greater increase from baselineA placebo-controlled trial examining atorvastatin in dyslipi-
in HDL-cholesterol (P  0.001) than patients receiving pla-demic patients undergoing CAPD.
cebo. The overall adverse event profile for atorvastatin wasBackground. Individuals with chronic renal disease are at
similar to that observed with placebo.high risk of cardiovascular morbidity and mortality, and there-
Conclusions. Atorvastatin was effective in achieving targetfore the management of dyslipidemia is particularly important
LDL-cholesterol levels in a high proportion of the dyslipidemicin this patient population. This double-blind randomized study
CAPD patients studied at doses that are well tolerated.investigated the efficacy and safety of the 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase inhibitor, ator-
vastatin, in continuous ambulatory peritoneal dialysis (CAPD)
patients with dyslipidemia.
Disturbances in plasma lipoprotein metabolism areMethods. Following a two- to four-week baseline period,
frequently observed among patients with end-stage renalpatients with low-density lipoprotein (LDL)-cholesterol 3.5
mmol/L (135 mg/dL) were randomized to receive either ator- disease, particularly those on dialysis. The combination
vastatin 10 mg (N  82) or placebo (N  95) for 16 weeks. If of dyslipidemia and other co-existent risk factors such
LDL-cholesterol remained 3.5 mmol/L, the dose of atorva- as hypertension, diabetes and obesity is likely to contrib-statin was titrated to 20 mg and 40 mg after four and eight
ute to the marked increase in the risk of cardiovascularweeks, respectively.
morbidity and mortality in individuals receiving dialysisResults. After four weeks a significantly greater proportion
of patients receiving atorvastatin 10 mg had achieved the LDL- relative to the general population [1].
cholesterol goal3.5 mmol/L compared with patients receiving In order to improve clinical practice in the prevention
placebo (85.4% vs. 16.0%; P  0.001). The statistically signifi- of coronary heart disease (CHD), various national andcant difference between the two groups was maintained at
international bodies have produced recommendationsweek 8 and week 16 (P  0.001 at both time points). At week
16, patients receiving atorvastatin had significantly greater re- based on data from clinical, epidemiological and obser-
ductions from baseline in LDL-cholesterol, total cholesterol, vational studies [2–4]. Central to such recommendations
triglycerides and total cholesterol:HDL-cholesterol ratio (all is the reduction of serum cholesterol levels, in particular
low-density lipoprotein (LDL) cholesterol. The high risk
1 The Atorvastatin in CAPD Study investigators who were involved in of cardiovascular events associated with chronic renal
the study include: P. Ackrill (Manchester); R.A. Banks (Gloucester); disease suggests that the management of LDL-choles-L. Barker (Reading); J.M. Boulton (Glasgow); E. Brown (London);
terol levels may be of particular importance in this pa-H. Cairns (London); P. Conlon (Dublin); R.A. Coward (Preston); R.
Fluck (Derby); R. Gokal (Manchester); D. Goldsmith (London); A. tient population.
Heaton (Norwich); R.M. Higgins (Coventry); L. Hill (Shrewsbury); Despite limited evidence for their effectiveness in di-J.J. Kwan (Carshalton); R.J.S. McGonigle (Plymouth); G. Mellotte
(Dublin); D. Oliveira (London); P. Stevens (Canterbury); J. O’Do- alysis patients, 3-hydroxy-3-methylglutaryl coenzyme A
noghue (Manchester); G. Venkat (Portsmouth); T.G. Feest (Bristol); (HMG-CoA) reductase inhibitors or statins have be-
R. Woolfson (London); P.A. Rutherford (Wrexham); P. Warwicker
come the most widely used class of drug in the treatment(Stevenage); C. Jones (York); A.J. Williams (Swansea); P.F. Williams
(Ipswich); R. Smith (Stourbridge); J. Taylor (Dorchester); and M. of hyperlipidemia complicating chronic renal disease.
Thomas (Birmingham). Atorvastatin is an established member of the statin class
that, over the dose range 10 to 40 mg/day, has been shownKey words: dyslipidemia, CAPD, LDL-cholesterol, atorvastatin, chronic
renal disease, lipoprotein metabolism. to provide statistically significant greater reductions in
LDL-cholesterol and total-cholesterol than milligram-Received for publication June 27, 2001
equivalent doses of simvastatin, pravastatin, lovastatinand in revised form October 22, 2001
Accepted for publication November 2, 2001 and fluvastatin [5]. Furthermore, at its maximum dose
of 80 mg/day, atorvastatin has been demonstrated to 2002 by the International Society of Nephrology
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reduce LDL-cholesterol levels by up to 61% and triglyc- Study design
eride levels by up to 45% [6]. Atorvastatin is also well At screening, patients meeting the study entry criteria
tolerated, and its ability to reduce LDL-cholesterol sig- provided a fasting blood sample for safety and lipid anal-
nificantly more than other statins does not appear to yses and commenced a two- to four-week baseline pe-
compromise its safety profile [7]. riod. Individuals who had previously received lipid-low-
The current study was designed to assess the efficacy ering agents needed to have discontinued therapy for at
and safety of atorvastatin in dyslipidemic patients with least three weeks prior to the screening visit.
chronic renal failure undergoing continuous ambulatory Patients with an LDL-cholesterol level 3.5 mmol/L
peritoneal dialysis (CAPD). (135 mg/dL) were randomized to receive either atorvas-
tatin 10 mg or placebo. If LDL-cholesterol remained
3.5 mmol/L, patients receiving atorvastatin were ti-METHODS
trated to 20 mg and then 40 mg after four and eight
The protocol was approved by the South Thames Multi- weeks, respectively. Patients were followed for 16 weeks.
centre Research Ethics Committee. Each participating Lipid results were reviewed centrally and instructions
investigator obtained approval from their Local Research on whether or not to titrate the dose of a patient were
Ethics Committee. provided to investigators by telephone by an indepen-
dent assessor. Titration was carried out in all atorvastatinPatient selection
patients failing to reach the LDL-cholesterol goal and
Men and women were considered eligible for study in 30% of placebo patients failing to reach the LDL-
entry if they were aged 18 years or older and had chronic cholesterol target; of the latter group, those who had
renal failure treated with automated peritoneal dialysis their ‘dose’ doubled were determined on a random basis.
(APD) or CAPD for at least three months. At screening, It was considered that if the dose was titrated in all
patients were required to have untreated dyslipidemia placebo patients who did not achieve the target LDL-
[defined as total cholesterol 5.2 mmol/L (200 mg/dL) cholesterol level, then investigators would be more likely
and LDL-cholesterol 3.5 mmol/L (135 mg/dL)] or dys- to associate patients who needed continual titration with
lipidemia uncontrolled by treatment with maximally tol- placebo treatment and patients who reached the LDL-
erated doses of other lipid-lowering agents taken for a cholesterol goal with atorvastatin treatment. This, in
minimum period of four weeks. turn, may have jeopardized the blinding of the study.
Exclusion criteria included women who were pregnant
Efficacy assessmentsor breastfeeding; active liver disease or hepatic dysfunc-
tion defined as plasma alanine aminotransferase (ALT) The primary efficacy parameter was the proportion of
or aspartate aminotransferase (AST) greater than three patients achieving an LDL-cholesterol target of 3.5
times the upper limit of normal (3 ULN); creatinine mmol/L (135 mg/dL). Secondary efficacy analyses were
kinase 3  ULN; hypersensitivity to HMG-CoA re- changes from baseline in total cholesterol, high-density
ductase inhibitors; concurrent therapy with long-term lipoprotein (HDL) cholesterol, triglycerides and the ra-
immunosuppressants; concurrent therapy with medica- tio of total cholesterol:HDL-cholesterol.
tion known to affect lipoprotein metabolism; concurrent
Safety assessmentstherapy with drugs known to be associated with rhab-
domyolysis in combination with HMG-CoA reductase Safety and tolerability were assessed by adverse event
inhibitors (such as cyclosporine, erythromycin, azole reporting and by the number of patients withdrawing
antifungals) and patients receiving concurrent fibrate due to adverse events. Adverse events were defined as
therapy; patients who had a myocardial infarction, percu- any untoward medical occurrence whether or not it was
taneous transluminal coronary angioplasty, coronary ar- considered as related to treatment. Routine hematologi-
tery bypass graft or transient ischemic attack within three cal and biochemical tests were conducted on all samples
months of study entry; non-stabilized diabetes mellitus at a central laboratory.
(this was to avoid enrollment of those patients with fre-
Statistical methodsquent changes in diabetic medication over the previous
3 to 6 months and those with brittle diabetes; patients A sample size calculation was used to determine the
with type 1 diabetes were not excluded from study entry number of patients required in each treatment group to
providing their diabetes was stabilized); history of alco- give the study 90% power to detect differences in pri-
hol abuse; participation in another clinical trial concur- mary and secondary efficacy parameters.
rently or within 30 days prior to study entry; clinical Statistical analyses were conducted on an intention
evidence of inflammatory muscle disease and total cho- to treat basis. Analysis of patients achieving the LDL-
cholesterol target was performed using a Mantel-Haens-lesterol 8.0 mmol/L (310 mg/dL).
Harris et al: Effects of atorvastatin in CAPD patients 1471
Table 1. Demographics and clinical characteristics ofzel 2 test, adjusting for geographic cluster. Secondary
total patient population
efficacy analyses on the percentage change in lipid pa-
Atorvastatin Placeborameters were carried out using analysis of covariance
Characteristic (N82) (N94)(ANCOVA), fitting geographic cluster, treatment group,
Gender N (%)and baseline value as covariates. Hypothesis tests were
Male 47 (57.3) 52 (55.3)
two-sided and P values 0.05 were considered statisti- Female 35 (42.7) 42 (44.7)
Ethnic group N (%)cally significant.
White/Caucasian 75 (91.5) 81 (86.2)
Black 3 (3.7) 3 (3.2)
Asian 4 (4.9) 8 (8.5)RESULTS
Other 0 (0) 2 (2.1)
Age years (meanSD) 56.715.4 57.513.5Patient characteristics
Weight kg (meanSD) 72.713.3 71.314.8
A total of 293 patients were recruited from 33 centers Body mass index kg/m2
(meanSD) 25.84.1 25.94.9in the UK and the Republic of Ireland. The first patient
CHD risk factors N (%)entered the study in November 1998 and the last patient
Family history of CHD/PVD 13 (15.9) 19 (20.2)
study observation was completed in February 2000. Of Hypertension 67 (81.7) 76 (80.9)
Smoking 18 (22.0) 17 (18.1)the original study population, 116 patients were discon-
Diabetes 10 (12.2) 12 (12.8)tinued during the baseline period. In the majority of cases
Obesitya 5 (6.1) 14 (14.9)
(62%) this was because total cholesterol was5.2 mmol/L Lack of exercise 34 (41.5) 44 (46.8)
Mean lipid levelb mmol/L(200 mg/dL) and/or LDL-cholesterol was 3.5 mmol/L
Total cholesterol 6.500.69 6.580.72(135 mg/dL), that is, they were not dyslipidemic as defined
LDL-cholesterol 4.500.62 4.520.64
by the study entry criteria. No patients were withdrawn HDL-cholesterol 1.060.28 1.130.31
Triglycerides 2.020.98 2.031.00due to abnormalities in their liver function or the use of
Total:HDL-cholesterol ratioc 6.551.94 6.291.92concurrent medication known either to affect lipoprotein
Abbreviations are: CHD, coronary heart disease; PVD, peripheral vascularmetabolism or to interfere with statin therapy.
disease; LDL, low-density lipoprotein; HDL, high-density lipoprotein.
Of the 82 patients randomized to receive atorvastatin, a Defined as body mass index 30 kg/m2
b Lipid values presented as mean  standard deviation (SD)59 (72%) completed the 16-week treatment period. Rea-
c Ratio has no units
sons for withdrawal were adverse events (13 patients),
transplantation (4 patients), and other reasons (6 pa-
tients). For the placebo group, 71 of the 95 patients
(75%) randomized to treatment completed the study. and 8 in the placebo group). The proportions of patients
undergoing CAPD (93% in the atorvastatin group andOne patient randomized to placebo withdrew prior to
receiving any treatment. Causes of withdrawal among 91% in the placebo group) and APD (7% in the atorva-
statin group and 9% in the placebo group) were similarthe other placebo-treated patients were adverse events
(11 patients), transplantation (2 patients), non-compli- in each treatment arm.
Patients in both study groups had multiple CHD riskance (1 patient), and other reasons (10 patients).
The clinical characteristics of patients at study entry factors, the most common of which was hypertension.
Risk factors were balanced between the treatment armsare shown in Table 1. There were no marked differences
between the two treatment groups in any of the baseline although a greater proportion of patients in the placebo
group were obese (defined as body mass index 30 kg/characteristics. Patients were assigned to atorvastatin or
placebo in a ratio of 1:1. Randomization was performed m2) compared with those in the atorvastatin group.
Six patients had been receiving lipid-lowering therapyaccording to a centrally prepared randomization list. Medi-
cation was packed according to this list and labeled with in the month prior to screening (5 patients on simvastatin
and 1 patient on atorvastatin). In all these patients, medi-consecutive patient numbers. Each site was allocated a
block (or blocks) of this numbered medication, which cation was stopped at least three weeks prior to the start
of study treatment.was then dispensed to the patients in strict numerical
order within that site. The apparent lack of balance be-
Efficacytween the two treatment groups with respect to the num-
ber of patients randomized is probably a result of the After four weeks, a significantly greater proportion of
patients receiving atorvastatin 10 mg had achieved thelarge number of centers in the study and the relatively
small number of patients recruited by each center. LDL-cholesterol goal 3.5 mmol/L compared with pa-
tients receiving placebo (85.4% vs 16.0%; P 0.001; Ta-Primary glomerulonephritis was the most common
cause of renal failure in the study population, accounting ble 2). At this time, seven patients receiving atorvasta-
tin required titration to the 20 mg dose. Of these, fourfor 18% of patients in both treatment groups. Of the pa-
tients who received study drug, 14 had previously under- achieved target LDL-cholesterol by week 8, 1 failed to
reach target, one patient withdrew due to an adversegone renal transplantation (6 in the atorvastatin group
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Table 2. Patients achieving the target LDL-cholesterol level of 3.5 mmol/L (135 mg/dL)
Atorvastatin (N82) Placebo (N94)
Number of Patients Patients at Patients Patients at
weeks completed (N) targetb % (N) completed (N) targetb % (N)
4 76 85.4a (70) 88 16.0 (15)
8 68 80.5a (66) 80 9.6 (9)
16 59 64.6a (53) 71 12.8 (12)
a P  0.001 vs. placebo
b Withdrawn patients were considered as having failed to reach target level
frequently reported individual adverse events are sum-
marized in Table 3.
No differences were apparent between the two treat-
ment groups with respect to effects on laboratory safety
parameters over the study period. Only two patients
(1 from each group) had AST and/or ALT levels that
exceeded 3ULN. The atorvastatin-treated patient was
withdrawn due to transaminasemia, but this was consid-
ered definitely not related to treatment. One patient
receiving atorvastatin had a creatinine kinase level3
ULN at two consecutive visits resulting in withdrawal
Fig. 1. Summary of percent change from baseline for lipid parameters (the actual levels recorded in this patient were between
for atorvastatin (; N  79) versus placebo (; N  89) at 16 weeks. 3 and 4  ULN).
Thirteen atorvastatin-treated patients (15.9%) and 11
patients (11.7%) treated with placebo were withdrawn
from the study as a result of adverse events. In the ator-
event, and lipid levels were unavailable for one patient vastatin group, 11 events resulting in withdrawal were
at week 8. No patients were titrated to atorvastatin 40 considered possibly, probably, or definitely related to
mg. The statistically significant difference between the the study drug compared with four events in the placebo
two groups in the proportion of patients reaching the group.
LDL-cholesterol goal was maintained at week 8 and
week 16 (P  0.001 at both time points).
DISCUSSIONAt week 16, patients receiving atorvastatin had signifi-
While the need to treat lipid abnormalities compli-cantly greater reductions from baseline in LDL-choles-
cating renal disease is unproven, it is reasonable to as-terol, total cholesterol, triglycerides, and total cholesterol:
sume that well-established cardiovascular risk factorsHDL-cholesterol ratio (all P  0.0001), and a signifi-
present the same health hazards to dialysis patients ascantly greater increase from baseline in HDL-cholesterol
they do to patients without renal disease. It seems likely,(P  0.001) than patients receiving placebo (Fig. 1).
therefore, that the high prevalence of dyslipidemia in
individuals receiving dialysis contributes to the elevatedSafety
risk of cardiovascular morbidity and mortality in this
Similar proportions of patients in both study arms
patient population.
experienced at least one adverse event. In addition, there In guidelines for the prevention of coronary heart dis-
were no differences between atorvastatin and placebo ease in clinical practice published by the Joint British
with regard to the overall incidence or severity of serious Societies, renal dysfunction is classified together with
adverse events. In 20 patients (24.4%) in the atorvastatin existing CHD and type 2 diabetes as diseases conferring
group and 26 patients (27.7%) in the placebo group, a high risk of future coronary events and for which lipid-
adverse events were considered definitely, probably or lowering therapy is recommended for all patients [2].
possibly related to treatment. Serious adverse events However, a recent survey of UK renal units demon-
were experienced by 16 patients (19.5%) receiving ator- strated that only 16% of dialysis patients were receiving
vastatin compared with 16 patients (17.0%) receiving treatment with lipid-lowering drugs (poster; Harris et al,
placebo. For three patients (1 receiving atorvastatin and The Renal Association 50th Annual Meeting, September
2 receiving placebo) the serious adverse event was con- 2000). Furthermore, of those patients on therapy only
50% had achieved an LDL-cholesterol goal of 3.0sidered to be related to the study treatment. The most
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Table 3. Most frequently reported adverse events
Atorvastatin (N82) Placebo (N94)
Adverse eventa All events Associatedb All events Associatedb
Peritonitis 10 (12.2) 0 (0.0) 10 (10.6) 0 (0.0)
Diarrhea 9 (11.0) 2 (2.4) 2 (2.1) 2 (2.1)
Pain (non-specified) 6 (7.3) 4 (4.9) 1 (1.1) 0 (0.0)
Constipation 6 (7.3) 3 (3.7) 9 (9.6) 3 (3.2)
Hypervolemia 5 (6.1) 0 (0.0) 7 (7.4) 0 (0.0)
Vomiting 5 (6.1) 0 (0.0) 6 (6.4) 3 (3.2)
Injection site reaction 5 (6.1) 1 (1.2) 6 (6.4) 0 (0.0)
Abdominal pain 1 (1.2) 1 (1.2) 6 (6.4) 1 (1.1)
Infection (non-specified) 5 (6.1) 0 (0.0) 4 (4.3) 0 (0.0)
Creatinine kinase increasec 5 (6.1) 5 (6.1) 3 (3.2) 3 (3.2)
Pruritis 1 (1.2) 0 (0.0) 5 (5.3) 3 (3.2)
Dyspepsia 3 (3.7) 1 (1.2) 5 (5.3) 2 (2.1)
Values are numbers of patients; % of treatment group is given in parentheses.
a Reported by 5 or more patients
b Definition of ‘associated’ is definitely, probably or possibly related to study drug
c Increase that was confirmed as above the upper limit of normal by at least one repeat test and that suggested a disease and/or organ toxicity of a severity that
required active management
mmol/L (115 mg/dL). These data suggest that more ag- eride and HDL-cholesterol levels beneficially is impor-
tant because abnormal concentrations of these lipidgressive treatment of dyslipidemia may be indicated in
this patient population. parameters characterize the usual pattern of dyslipide-
mia observed in uremic patients and may also contributeThe reduction in LDL-cholesterol with atorvastatin
observed in our study was similar to that reported using to the elevated cardiovascular risk seen in dialysis pa-
tients [13].similar doses of the drug in non-renal patients [8–10].
This was as expected as renal dysfunction has previously In non-renal patients, atorvastatin 10 to 80 mg/day has
been shown to be well tolerated in clinical trials of upbeen demonstrated not to alter the pharmacokinetics or
LDL-cholesterol reduction of atorvastatin [11]. to two years involving over 2500 patients [7]. The rate
of serious adverse events and proportion of patientsAfter four weeks of treatment 85% of CAPD patients
receiving atorvastatin 10 mg had achieved the LDL-cho- withdrawing due to adverse events was greater in this
trial than previously reported for atorvastatin. However,lesterol goal of 3.5 mmol/L (135 mg/dL). The conse-
quent slight reduction in the proportion of patients the nature of the patient population could reasonably
explain this observation, as participants had severe renalreaching the goal at 16 weeks may be due to the nature
of this patient population, but is more likely to be a impairment at study initiation and therefore the inci-
dence of concomitant illness is always likely to be higherfunction of the way the results were analyzed. For the
purpose of calculation, individuals who did not complete than in non-renal patients. The overall adverse event
profile for atorvastatin was similar to that observed withthe study were considered as having failed to reach goal.
However, if withdrawn patients were instead omitted placebo. The incidence of drug-related adverse events
and the proportion of patients withdrawn from the studyfrom the final analysis, the proportion of patients reach-
ing the LDL-cholesterol target at 16 weeks was 89.8%. also were comparable in the atorvastatin and placebo
groups. No dose-dependent adverse effects were observedThe LDL-cholesterol target level we used was that
recommended by the European Atherosclerosis Society among patients treated with atorvastatin. There was a
disparity between groups in the number of withdrawalsat the time of study design [12]. However, more recent
guidelines have adopted lower LDL-cholesterol goals. due to events considered possibly, probably or definitely
related to the study drug. Further analysis of these data,Guidelines issued by the Joint British Societies and
recently endorsed by the UK government’s National however, showed that the number of withdrawals due
to events that were probably or definitely drug-relatedService Framework for Coronary Heart Disease recom-
mend a lower LDL-cholesterol treatment goal of 3.0 was similar for atorvastatin (2 events—muscle pain; ar-
thralgia) and placebo (3 events—hepatitis; myocardialmmol/L for both primary and secondary prevention of
CHD [2]. Re-analysis of the current data showed that infarction; nausea). Elevations of liver transaminases
and creatinine kinase 3  ULN occurred in atorvas-69.5% of patients had achieved this lower treatment
target after four weeks on atorvastatin 10 mg. tatin and placebo groups at similar low rates.
While the results of this study demonstrate that ator-Atorvastatin also reduced triglyceride and increased
HDL-cholesterol concentrations from baseline signifi- vastatin effectively lowers lipids in individuals undergo-
ing CAPD, there is still a pressing need for large prospec-cantly more than placebo. This ability to modify triglyc-
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